Accession Therapeutics
Generated by Meeveem AI
"Precision viral immunotherapies targeting intractable cancers with novel Trocept technology"
Oxford
•11 - 50 Employees
•Biotechnology
About Accession Therapeutics
Accession Therapeutics develops first in class immunotherapies using Trocept, a stealth virus platform that targets cancer cells with precision while bypassing healthy tissue. The technology harnesses tumour specific integrins to deliver potent payloads directly to solid tumours, eliminating limitations of current immunotherapies that struggle with tumour diversity. The company's lead programme, TROCEPT-01, is recruiting patients in a Phase 1 clinical trial for advanced solid cancers. Founded by immuno-oncology pioneer Bent Jakobsen, Accession advances a pipeline of engineered candidates designed to eradicate cancer cells regardless of tumour heterogeneity, offering new treatment options for patients with difficult to treat disease.
46
Team Members
2020
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A world where every patient with advanced cancer can access precisely targeted treatments that eradicate tumours completely, transforming survival outcomes for the most intractable forms of the disease.
Our Mission
Accession Therapeutics develops novel tumour-activated immunotherapies that combine viral precision targeting with potent therapeutic payloads to eradicate cancer cells across diverse solid tumours.